The study identifies PAD2 as a viable target for developing neuroprotective therapies.
In contrast, PAD4 blockade does not exhibit the same beneficial effects on recovery from traumatic brain injury.
This research supports further investigation of PAD2 for developing new treatments in neuroprotection.
Abstract
Our results suggest that PAD2, but not PAD4, blockade can improve outcomes following TBI, which justifies its exploration as a potential target for novel neuroprotective therapies.